WHY IT MATTERS: Patients managing anxiety who are curious about cannabis now have additional research supporting CBD-dominant products as a potentially effective option worth discussing with a knowledgeable clinician before making any changes to current treatment. CLINICAL OVERVIEW: CBD-dominant cannabis products are gaining clinical attention as a potential option for anxiety management, with research suggesting meaningful symptom relief in patients who use formulations where cannabidiol predominates over THC. The anxiolytic properties of CBD are thought to involve serotonergic signaling and modulation of the endocannabinoid system, particularly at CB1 receptors and 5-HT1A receptors, which distinguishes its mechanism from both benzodiazepines and SSRIs.